

**Vaccine Research and Development Initiatives
National Institute of Allergy and Infectious Diseases (continued)**

Research Objective	Estimated First Year cost	Initiatives	Category
Evaluate Candidate Vaccine(s) in Phase III Trials	FY 93: \$200,000	Field evaluation of hepatitis A vaccine in an epidemic	R&D
		Conduct clinical trials of pneumonia vaccines in children	R&D
	FY 94: \$6,000,000	Establish field sites for vaccine evaluation in endemic areas	Emerging R&D
		Research on pathogenesis of Lyme disease, and clinical evaluation of candidate Lyme disease vaccines	R&D
		Influenza pandemic preparedness	Emerging
TOTALS	FY 93: \$4,200,000 FY 94: \$35,500,000		